A new publication regarding vosoritide was listed on October 1, 2026. The item is a correspondence titled "Correspondence on 'Real-world outcomes of vosoritide in achondroplasia: A systematic review and meta-analysis of multinational clinical evidence' by Albuquerque et al." It appears in Genetics in Medicine, the official journal of the American College of Medical Genetics.
This entry is a correspondence piece responding to an earlier systematic review and meta-analysis that examined multinational clinical evidence on vosoritide use in achondroplasia. The publication record does not include details of the correspondence's content, arguments, or conclusions. No findings, data points, or results from either the original meta-analysis or the correspondence are provided in the available record.
Vosoritide remains an approved therapy. This listing reflects only that a correspondence related to prior published evidence on the compound has appeared in the literature. Readers interested in the full scope of the discussion, including any points raised in the correspondence or the original meta-analysis it addresses, should consult the journal source directly for complete context.
For more background on this compound, see the linked overview page.